Table 2.
Material | HA a MW b (KDa)/ Functional Groups |
DM (%) c/ Functionalization |
Cross-Linking Reaction/Cross-Linker/Gelation Onset (s) | Bioactive Agent/Stimulation/Extra | Cell Type/Cell Number per mL | Outcome |
---|---|---|---|---|---|---|
Redox/enzymatic reaction | ||||||
HTG d [57] | -/COOH | 13.38/- | Enzymatic/tyrosinase/108–132 | EGCG e/- | Porcine chondrocytes/2 × 107 |
|
HA-GEL h [59] | 350/COOH | -/- | Redox/HRP i and H2O2/- | -/electrical | Porcine MSCs j/1 × 106 |
|
HA-TA k [52] | 70/COOH | 24 | Oxidative coupling reaction (redox)/HRP i and H2O2/10–500 | Platelet lysate | MSCs j/107 |
|
HA a [60] | 1010–1800/COOH | /transglutaminase substrate peptides | Enzymatic/thrombin, factor XIII, transglutaminase-modified heparin/60–120 | TGF-β m/- | Human infant chondrocytes/5, 10 or 15 × 106, |
|
HA a [50] | 1010–1800/COOH | /transglutaminase substrate peptides, heparin | Enzymatic/thrombin, transglutaminase factor XIII/900 | TGF-β m/- | Human chondroprogenitor cells (fetal origin)/15 × 106 |
|
HA-MA-PNIPAAm-CL n [61] | 2000/OH | 30/- | Redox/-/- | -/- | Rabbit adipose-derived stem cells/1 × 106 |
|
PVCL-g-HA o (methacrylate HA) [62] | 58 and 1100/OH | -/- | Redox/VA-057 p initiator/- | -/- | Bovine chondrocytes/3.65 × 106 |
|
HA-Tyr k [63] | 90/COOH | 6/- | Oxidative coupling reaction (Redox)/HRP i and H2O2/60 | Caprine MSCs j/107 |
|
|
Michael-type addition reaction | ||||||
MeHA q [2] | 66–99/OH | 46.5 ± 5.5/- 46.5 ± 5.5/CS r-binding peptide 46.5 ± 5.5/- |
Michael-type addition/MMP7 s-degradable peptide/457 ± 68.1 | -/- | MSCs j/1 × 106 chondrocytes/1.25 × 106 |
|
Hyper-branched PEGDA t-thiolated HA [56] | -/COOH | -/- | Michael-type addition/-/120 | -/- | Human AFF-MSCs u/5 × 106 |
|
MA-HA v [64] | 59/COOH | 30/- | Michael-type addition/MMP w-cleavable peptides/- | -/- | Human MSCs j/20 × 106 |
|
Schiff base reaction | ||||||
Glycol chitosan-oxidized HA a [65] | 100/OH | 33.4/- | Schiff base reaction/-/- | Cartilage ECM f particles/- | BMSCs x/2 × 107 |
|
Collagen-HAD z [66] | 1500–1800/ | -/- | Schiff base reaction/-/- | -/- | Rabbit chondrocytes/5 × 104 |
|
CH-HAD aa [53] | -/OH | 50/- | Schiff base raction//25–60 | -/- | Rabbit chondrocytes/5 × 106 |
|
OHA/GC ab [67] | 1000/OH | ~6.8–33.8/- | Schiff base raction//97–120 | -/- | ATDC5 chondrogenic cell line/106 |
|
Photocross-linking | ||||||
AHAMA ac [55] | 100–200/OH | 24/- | Photopolymerization/Irgacure 2959/- | -/- | BMSCs x/5 × 106 |
|
mGL/mHA ad [58] | 66–99/OH | Photocross-linking/LAP ae | Human BMSCs x/ 20 × 106 |
|
||
GelMA af/HAMA ag [68] | 860/OH | Photocross-linking/LAP ae and visible light (405 nm), Irgacure 2959 and UV ah light (365 nm) | /MEW-mPCL ai reinforcement | Human articular chondrocytes/107 |
|
|
MeHA ag [69] | 75/OH | 37/± HAV, ADAM-cleavable domain | Photocross-linking/Irgacure 2959 | MSCs j/20 × 106 |
|
|
MeHA ag/ELP aj [70] | 1600/OH | Photocross-linking/ | ZnO ak (antimicrobial) | Human MSCs j, NIH-3T3/2 × 106, 5 × 106 |
|
|
MeHA ag [71] | 1000/OH | 1.2/ | Photocross-linking/Irgacure 2959 | TGFβ3 m/DCC al or DVC am microparticles | Rat BMSC x/20 × 106 |
|
MeHA ag [72] | 74/OH | Photocross-linking/Irgacure 2959 | TGFβ3 m | Allogeneic MSCs j/60 × 106 |
|
|
MeHA ag, MeHA ag+ColI an, MeHA ag+MeCS ao [73] | 74/OH | 30 | Photocross-linking/Irgacure 2959 | Human MSCs j/20 × 106 |
|
|
MeHA ag [74] | 74/OH | 29 | Photocross-linking/Irgacure 2959 | Human MSCs j/20 × 106 |
|
|
Fibrinogen/HA-MA ag [75] | 1500–1800/OH | 95 ± 13/- | Ionic and chemical interactions, Photocross-linking/Irgacure 2959/ | TGFβ m/- | BMSCs x/104/well |
|
GelMA af and HA-MA ag [76] | 860/OH | Photocross-linking/Irgacure 2959/900 | Human chondrocytes/107 |
|
||
MeHA ag [77] | 74/OH | 27 | Photocross-linking/Irgacure 2959 | MSCs j and/or chondrocytes/20 × 106 |
|
|
Self-cross-linking and other reactions | ||||||
ColI an/HA-sNHS ap [78] | 61/COOH | 32, 50, 83/ | Self-cross-linking/no initiators and no cross-linkers/93–130 | Rabbit chondrocytes/5 × 106 |
|
|
HA-SH aq/GelSH ar, HA-SH aq/GelMA af, HA-SH aq/Gel as [79] | 340/COOH | 35.3/ | Strong disulfide bonding between HA-SH aq and GelSH ar/7.19, Michael addition between HA-SH aq and GelMA af/7.31, Physical interaction/7.27 |
-/- | Rabbit chondrocytes/3 × 106 |
|
Thiolated HA a—collagen [32] | 100, 300, 1000/COOH | -/- | Formation of disulfide bonds/thiolated icariin/1800 | -/- | Chondrocytes/5 × 106 |
|
Thiolated HA—collagen I [54] | 300/COOH | -/- | Self-cross-linking/10 | -/- | Rabbit chondrocytes/5 × 106 |
|
HA a-ADH at/PAD au, HA a-ADH at/PAD-RGD av [80] | 740/COOH | 41.5/- | Hydrazone reaction/PAD-RGD av/112–399 | -/- | Chondrocytes/6 × 106 |
|
a Hyaluronic acid, b molecular weight, c degree of modification, d tyramine-modified hyaluronic acid-gelatin, e epigallocatechin-3-gallate, f extracellular matrix, g osteoarthritis, h tyramine-modified hyaluronic acid—tyramine-modified gelatin, i horseradish peroxidase, j mesenchymal stem cells, k hyaluronic acid tyramine hydrogel, l hyaluronic acid tyramine hydrogel with platelet lysate, m transforming growth factor beta, n methacrylated hyaluronic acid cross-linked poly(N-isopropylacrylamide), o poly(N-vinylcaprolactam) and methacrylated hyaluronic acid, p 2,20-azobis[N-(2-carboxyethyl)22-methylpropionamidine]hydrate, q methacrylated hyaluronic acid, r chondroitin sulfate, s matrix metalloproteinase 7, t poly(ethylene glycol) diacrylate, u arthroscopic flushing-fluid-derived mesenchymal stem cells, v maleimide-modified HA, w matrix metalloproteinase, x bone marrow mesenchymal stem cells, y glycosaminoglycans, z hyaluronic acid dialdehyde, aa chitosan–hyaluronic acid dialdehyde, ab oxidized hyaluronate/glycol chitosan, ac methacrylated aldehyde-modified hyaluronic acid, ad methacrylated gelatin-methacrylated hyaluronic acid, ae lithium phenyl-2,4,6-trimethylbenzoylphosphinate, af gelatin methacryloyl, ag hyaluronic acid methacrylate (or methacrylated hyaluronic acid), ah ultraviolet, ai melt-electrowritten medical-grade polycaprolactone, aj elastin-like polypeptide, ak zinc oxide, al decellularized cartilage, am devitalized cartilage, an type I collagen, ao methacrylated chondroitin sulfate, ap N-hydroxysulfosuccinimide-activated hyaluronic acid, aq thiolated hyaluronic acid, ar thiolated gelatin, as gelatin, at adipic dihydrazide, au pectin dialdehyde, av aldehyde groups of G4RGDS-grafted aldehyde pectin.